What does this research mean for the field?

Initial stage and sarcoma type are critical parameters affecting prognosis in patients with primary brain sarcoma, with a median survival time of 106 months. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The aim is to evaluate the prognosis of patients diagnosed with primary brain sarcoma.

March 12, 2026Open Access

81MO Final analysis of the pan-European Arcagen study for molecular profiling and access to treatment for rare cancers: A joint EORTC-EURACAN initiative

Key Points

The aim is to evaluate the prognosis of patients diagnosed with primary brain sarcoma.
Conducted a retrospective cohort study using the SEER database from 2000 to 2022
Collected demographic, clinicopathological, and treatment information
Analyzed survival outcomes with Kaplan-Meier method
Used multivariate Cox proportional hazards models to identify independent prognostic factors
266 patients analyzed, with 71.1% under 60 years of age
1-year survival rate was 75%, 3-year was 63.4%, and 5-year was 57.7%
Age, gender, sarcoma type, and stage at diagnosis were significant prognostic factors
87.9% of patients underwent surgery, with 58.2% receiving radiotherapy

Abstract

Background: Primary brain sarcomas are exceedingly rare mesenchymal tumors of the central nervous system, representing a very small proportion of intracranial malignancies.Our aim in this study was to determine the prognosis of patients with brain sarcoma.Methods: This retrospective cohort study was conducted using the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with primary brain sarcoma between 2000 and 2022.Demographic, clinicopathological, and treatment information were collected.Survival outcomes were analyzed using the Kaplan-Meier method, and independent prognostic factors were determined with multivariate Cox proportional hazards models.Results: Analysis was performed using data from 266 patients who met the study criteria.The majority of patients were under 60 years of age (71.1%).The most common brain regions affected were the frontal (29.6%), parietal (15.7%), and temporal (15.3%) lobes.The most common sarcoma types were solitary fibrous tumor (32.7%), sarcoma, NOS (20.3%), spindle cell sarcoma (9%), and rhabdomyosarcoma (7.1%).Patients were more often diagnosed in the early stage (localized-74.4% and locally advanced-17.9%).Cancer-related surgery was performed in 87.9% of patients, 58.2% received radiotherapy, and 25.9% received chemotherapy.In patients with metastatic disease, the most common sites of metastasis were the lung (2.6%) and liver (1.1%).The 1-, 3-, and 5-year survival rates were 75%, 63.4%, and 57.7%, respectively.The median survival time was 106 months (95% CI,).Factors affecting survival were evaluated using multivariate analysis and were identified as age (p<0.001),gender (p=0.007),sarcoma type (p<0.001),tumor site (p=0.183),surgery (p=0.854),radiotherapy (p<0.001),chemotherapy (p=0.380), and stage at diagnosis (p=0.004). Conclusions:This study demonstrates the clinicopathological features and prognoses at diagnosis in patients with brain sarcoma, a rare condition.Initial stage and sarcoma type were identified as the most critical parameters affecting disease prognosis.Although surgery is the primary treatment for sarcoma, we detected that radiotherapy affects prognosis as an independent variable.

Bookmark

View Full Paper

Cite This Study

Morfouace et al. (Sun,) studied this question.

synapsesocial.com/papers/69b2581996eeacc4fcec757f https://doi.org/https://doi.org/10.1016/j.esmorc.2026.100287

Bookmark

View Full Paper